The OIS Innovator Award went to Sue Washer, Bill Hauswirth, and Nick Muzyczka for their pioneering role in gene therapy company AGTC. Washer and Hauswirth sit down with OIS Co-Chair Gil Kliman to share the tale of starting and leading the ophthalmology leader.
Gilbert H. Kliman, MD
Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health.
Sue Washer, President and CEO of AGTC, is an experienced entrepreneur with a strong scientific and operational background. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Entrepreneurship program.
William W. Hauswirth
Dr. Hauswirth received his B.S. in Chemistry from Stanford University and his Ph.D in Physical Chemistry from Oregon State University. After an NIH Fellowship in the Biochemistry Department at Johns Hopkins University, he joined that department as an Assistant Professor.
Dr. Muzyczka received his PhD in biochemistry from Johns Hopkins University in 1974. He then began working on the development of gene therapy vectors.